{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:43:24Z","timestamp":1792453404476,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020377","name":"Maruho Takagi Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016730","name":"Torii Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40257-026-01033-2","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:15:35Z","timestamp":1777277735000},"page":"831-839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["48-Week Real-World Outcomes of Lebrikizumab Treatment for Atopic Dermatitis: Systemic Therapy-Naive Versus -Experienced Patients"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-9596","authenticated-orcid":false,"given":"Teppei","family":"Hagino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eita","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei-ichiro","family":"Motegi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"4","key":"1033_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jaci.2020.02.008","volume":"145","author":"T Honda","year":"2020","unstructured":"Honda T, Kabashima K. Reconciling innate and acquired immunity in atopic dermatitis. J Allergy Clin Immunol. 2020;145(4):1136\u20137. https:\/\/doi.org\/10.1016\/j.jaci.2020.02.008.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1033_CR2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jaci.2006.12.646","volume":"119","author":"T Nomura","year":"2007","unstructured":"Nomura T, Sandilands A, Akiyama M, et al. Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol. 2007;119(2):434\u201340. https:\/\/doi.org\/10.1016\/j.jaci.2006.12.646.","journal-title":"J Allergy Clin Immunol"},{"issue":"10247","key":"1033_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360. https:\/\/doi.org\/10.1016\/s0140-6736(20)31286-1.","journal-title":"Lancet"},{"issue":"1","key":"1033_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-025-03910-y","volume":"317","author":"JI Silverberg","year":"2025","unstructured":"Silverberg JI, Anderson P, Cappelleri JC, et al. Burden of mild and moderate atopic dermatitis in adults: results from a real-world study in the United States. Arch Dermatol Res. 2025;317(1):556. https:\/\/doi.org\/10.1007\/s00403-025-03910-y.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"1033_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54\u201362. https:\/\/doi.org\/10.1111\/all.13954.","journal-title":"Allergy"},{"issue":"1","key":"1033_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/1744666x.2020.1858802","volume":"17","author":"C Tubau","year":"2021","unstructured":"Tubau C, Puig L. Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Rev Clin Immunol. 2021;17(1):15\u201325. https:\/\/doi.org\/10.1080\/1744666x.2020.1858802.","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"1033_CR7","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s13555-023-00947-7","volume":"13","author":"AJ Okragly","year":"2023","unstructured":"Okragly AJ, Ryuzoji A, Wulur I, et al. Binding, Neutralization and internalization of the interleukin-13 antibody, lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535\u201347. https:\/\/doi.org\/10.1007\/s13555-023-00947-7.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"16","key":"1033_CR8","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2217\/imt-2022-0307","volume":"15","author":"AR Ewulu","year":"2023","unstructured":"Ewulu AR, Prajapati S, Feldman SR. The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents. Immunotherapy. 2023;15(16):1341\u20139. https:\/\/doi.org\/10.2217\/imt-2022-0307.","journal-title":"Immunotherapy"},{"issue":"11","key":"1033_CR9","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1111\/all.15811","volume":"78","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Guttman-Yassky E, Eichenfield LF, et al. Tralokinumab therapy for moderate-to-severe atopic dermatitis: clinical outcomes with targeted IL-13 inhibition. Allergy. 2023;78(11):2875\u201391. https:\/\/doi.org\/10.1111\/all.15811.","journal-title":"Allergy"},{"key":"1033_CR10","doi-asserted-by":"publisher","unstructured":"Hagino T, Uchiyama A, Kosaka K, et al. A 48-week real-world outcome of tralokinumab treatment for atopic dermatitis: systemic therapy-na\u00efve versus-experienced patients. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.09.034","DOI":"10.1016\/j.jaad.2025.09.034"},{"issue":"12","key":"1033_CR11","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2206714.","journal-title":"N Engl J Med"},{"issue":"6","key":"1033_CR12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/bjd\/ljad022","volume":"188","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740\u20138. https:\/\/doi.org\/10.1093\/bjd\/ljad022.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1033_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","volume":"159","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. 2023;159(2):182\u201391. https:\/\/doi.org\/10.1001\/jamadermatol.2022.5534.","journal-title":"JAMA Dermatol"},{"key":"1033_CR14","doi-asserted-by":"publisher","unstructured":"Rob F, Gkalpakiotis S, Kojanov\u00e1 M, et al. Efficacy and safety of lebrikizumab in atopic dermatitis over 24\u2009weeks: an analysis from the BIOREP registry. J Eur Acad Dermatol Venereol. 2025;https:\/\/doi.org\/10.1111\/jdv.70009","DOI":"10.1111\/jdv.70009"},{"key":"1033_CR15","doi-asserted-by":"publisher","unstructured":"Hagino T, Uchiyama A, Onda M, et al. 24-Week real-world effectiveness and safety of lebrikizumab for atopic dermatitis in Japan: an analysis stratified by prior systemic therapy. Dermatitis. 2025;https:\/\/doi.org\/10.1089\/derm.2025.0045","DOI":"10.1089\/derm.2025.0045"},{"issue":"2","key":"1033_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4168\/aair.2017.9.2.158","volume":"9","author":"H Chu","year":"2017","unstructured":"Chu H, Shin JU, Park CO, Lee H, Lee J, Lee KH. Clinical diversity of atopic dermatitis: a review of 5000 patients at a single institute. Allergy Asthma Immunol Res. 2017;9(2):158\u201368. https:\/\/doi.org\/10.4168\/aair.2017.9.2.158.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"5","key":"1033_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/ced.14134","volume":"45","author":"A Livesey","year":"2020","unstructured":"Livesey A, Garty F, Shipman AR, Shipman KE. Lactate dehydrogenase in dermatology practice. Clin Exp Dermatol. 2020;45(5):539\u201343. https:\/\/doi.org\/10.1111\/ced.14134.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1033_CR18","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.alit.2022.06.009","volume":"71","author":"H Saeki","year":"2022","unstructured":"Saeki H, Ohya Y, Furuta J, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022;71(4):448\u201358. https:\/\/doi.org\/10.1016\/j.alit.2022.06.009.","journal-title":"Allergol Int"},{"issue":"2","key":"1033_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.alit.2025.01.003","volume":"74","author":"H Saeki","year":"2025","unstructured":"Saeki H, Ohya Y, Arakawa H, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024. Allergol Int. 2025;74(2):210\u201321. https:\/\/doi.org\/10.1016\/j.alit.2025.01.003.","journal-title":"Allergol Int"},{"issue":"8","key":"1033_CR20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573\u20137. https:\/\/doi.org\/10.7326\/0003-4819-147-8-200710160-00010.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1033_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"1033_CR22","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/1346-8138.16950","volume":"50","author":"T Hagino","year":"2023","unstructured":"Hagino T, Yoshida M, Hamada R, Fujimoto E, Saeki H, Kanda N. Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with moderate-to-severe atopic dermatitis. J Dermatol. 2023;50(12):1576\u201384. https:\/\/doi.org\/10.1111\/1346-8138.16950.","journal-title":"J Dermatol"},{"issue":"2","key":"1033_CR23","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1111\/jdv.17705","volume":"36","author":"G Licata","year":"2022","unstructured":"Licata G, Gambardella A, Tancredi V, et al. Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib. J Eur Acad Dermatol Venereol. 2022;36(2):e150\u20132. https:\/\/doi.org\/10.1111\/jdv.17705.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1033_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/der.0000000000000590","volume":"31","author":"J Jaros","year":"2020","unstructured":"Jaros J, Hendricks AJ, Shi VY, Lio PA. A practical approach to recalcitrant face and neck dermatitis in atopic dermatitis. Dermatitis. 2020;31(3):169\u201377. https:\/\/doi.org\/10.1097\/der.0000000000000590.","journal-title":"Dermatitis"},{"issue":"1","key":"1033_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2212095","volume":"34","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis. J Dermatolog Treat. 2023;34(1):2212095. https:\/\/doi.org\/10.1080\/09546634.2023.2212095.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1033_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.alit.2024.08.010","volume":"74","author":"M Kido-Nakahara","year":"2025","unstructured":"Kido-Nakahara M, Chiba T, Mizusawa Y, et al. Cytokine profile of the stratum corneum in atopic dermatitis lesions differs between the face and the trunk. Allergol Int. 2025;74(2):222\u201332. https:\/\/doi.org\/10.1016\/j.alit.2024.08.010.","journal-title":"Allergol Int"},{"key":"1033_CR27","doi-asserted-by":"publisher","unstructured":"Hagino T, Uchiyama A, Onda M, et al. Real-world effectiveness and safety of lebrikizumab for moderate-to-severe atopic dermatitis: a 16-week study in Japan. Dermatitis; 2025. https:\/\/doi.org\/10.1089\/derm.2025.0004","DOI":"10.1089\/derm.2025.0004"},{"issue":"3","key":"1033_CR28","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.alit.2016.12.002","volume":"66","author":"M Furue","year":"2017","unstructured":"Furue M, Chiba T, Tsuji G, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017;66(3):398\u2013403. https:\/\/doi.org\/10.1016\/j.alit.2016.12.002.","journal-title":"Allergol Int"},{"issue":"3","key":"1033_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/1346-8138.12440","volume":"41","author":"Y Kataoka","year":"2014","unstructured":"Kataoka Y. Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis. J Dermatol. 2014;41(3):221\u20139. https:\/\/doi.org\/10.1111\/1346-8138.12440.","journal-title":"J Dermatol"},{"issue":"3","key":"1033_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.18176\/jiaci.0823","volume":"32","author":"JM Olaguibel","year":"2022","unstructured":"Olaguibel JM, Sastre J, Rodr\u00edguez JM, Del Pozo V. Eosinophilia induced by blocking the IL-4\/IL-13 pathway: potential mechanisms and clinical outcomes. J Investig Allergol Clin Immunol. 2022;32(3):165\u201380. https:\/\/doi.org\/10.18176\/jiaci.0823.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"5","key":"1033_CR31","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jaad.2025.01.052","volume":"92","author":"T Hagino","year":"2025","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: systemic therapy-naive versus -experienced patients. J Am Acad Dermatol. 2025;92(5):1049\u201355. https:\/\/doi.org\/10.1016\/j.jaad.2025.01.052.","journal-title":"J Am Acad Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01033-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01033-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01033-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:21:41Z","timestamp":1784186501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01033-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1033"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01033-2","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hidehisa Saeki, Teppei Hagino, Sei-ichiro Motegi and Naoko Kanda received lecture fees from Eli Lilly. The other authors have no conflicts of interest to be disclosed.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors significantly contributed to the manuscript and agreed with its contents. All authors read and approved the final version of the manuscript. Teppei Hagino conceptualized the study and mainly organized the manuscript. Naoko Kanda supervised the study. Akihiko Uchiyama, Hidehisa Saeki, Sei-ichiro Motegi, and Eita Fujimoto revised the manuscript.","order":2,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and its later amendments, and was approved by the institutional review boards of Gunma University, Nippon Medical School, and Nippon Medical School Chiba Hokusoh Hospital. (ethics approval number: HS2022-169).","order":3,"name":"Ethics","label":"Ethics Statements","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all the subjects involved in the study.","order":6,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}